Mileutis Strengthens Leadership with New Board Appointments
Mileutis enhances its leadership team in the animal health sector.
Mileutis, a leading biopharmaceutical company devoted to transforming the dairy industry, has recently appointed two distinguished executives to its Board of Directors. Dr. Joachim Hasenmaier and Mr. Aaron Schacht bring with them exceptional experience and insights as Mileutis embarks on its next phase of growth toward antibiotic and hormone-free solutions in animal health.
Dr. Joachim Hasenmaier comes to Mileutis with over three decades of expertise in both animal and human health sectors. His prior role as a Board Member and Head of Animal Health at Boehringer Ingelheim was pivotal in establishing the division as a global contender through strategic growth tactics, including acquisitions and businesses expansion. He is currently serving as Chair of the boards at IMV Technologies and ECO Animal Health, bolstered by advanced degrees in veterinary medicine, virology/immunology, and management from Kellogg School of Management.
Expressing his enthusiasm, Dr. Hasenmaier stated, "I've witnessed the crucial demand for sustainable alternatives to antibiotics within animal health. Mileutis is committed to fulfilling that need, and I am eager to assist in their advancement within the dairy sector." His vision aligns perfectly with the company's objectives to innovate responsibly.
Mr. Aaron Schacht functions as the CEO of BiomEdit, Inc., a biotech firm supported by the Gates Foundation that specializes in microbiome and synthetic biology advancements for animal health. Formerly, he directed R&D and Business Development at Elanco Animal Health, influencing significant acquisitions and introducing novel products that paved the way for Elanco's IPO after its separation from Eli Lilly. With 25 years of service at Lilly in senior roles, Schacht possesses a wealth of knowledge in strategy and innovation.
"Mileutis is confronting some of the dairy industry's most pressing issues," Mr. Schacht remarked. "It's an honor to join a team that is ready to launch antibiotic and hormone-free products, addressing the urgent challenge posed by antimicrobial resistance (AMR)." His commitment reflects a growing recognition within the industry of the need for effective solutions.
At present, Mileutis is in the process of developing peptide-based therapies like IMILAC™ and MILAC™, which are anticipated to revolutionize the market by providing a residue-free product range, creating a sustainable future for all stakeholders in the dairy sector.
David Javier Iscovich, the CEO and Chairman of Mileutis, commented on these strategic appointments. He noted, "The inclusion of Dr. Hasenmaier and Mr. Schacht is a landmark achievement for Mileutis. Their profound understanding of the animal health landscape, paired with extensive experience in driving innovation and growth, will significantly elevate Mileutis' impact on transforming the dairy industry." Through their leadership, the company aims to enhance its contributions to the agricultural field.
About Mileutis
Mileutis stands as a clinical-stage biopharmaceutical company dedicated to creating natural, peptide-based therapies that revolutionize animal health and food production. Its flagship product, IMILAC™, is a patented biologic aimed at replacing antibiotics for mastitis treatment, a common ailment among dairy cows. Prioritizing animal welfare, milk quality, and sustainable practices, Mileutis is set on promoting a more effective future for global dairy farming.
Frequently Asked Questions
What is the focus of Mileutis?
Mileutis concentrates on developing antibiotic and hormone-free solutions to improve animal health in the dairy industry.
Who are the recent appointments made to Mileutis's Board?
Dr. Joachim Hasenmaier and Mr. Aaron Schacht have been appointed to the Board of Directors of Mileutis.
What experience do the new board members bring?
Both appointments come with extensive expertise in healthcare, particularly in animal health and biotechnology, enhancing Mileutis's leadership team.
What products is Mileutis currently developing?
Mileutis is working on peptide-based therapies IMILAC™ and MILAC™, designed as residue-free alternatives for the dairy industry.
What is Mileutis's vision for the future?
The company's vision is to promote sustainable practices in dairy farming while enhancing animal welfare and milk quality.
